UroGen Pharma (NASDAQ:URGN) PT Lowered to $32.00 at Oppenheimer

UroGen Pharma (NASDAQ:URGN – Free Report) had its price target cut by Oppenheimer from $34.00 to $32.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have an outperform rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $54.00 target price on shares of UroGen Pharma […]

Related Keywords

China ,Urogen Pharma ,Mark Schoenberg ,Urogen Pharma Ltd ,Nasdaq ,Connor Clark Lunn Investment Management Ltd ,China Universal Asset Management Co ,Allspring Global Investments Holdings ,Jump Financial ,Securities Exchange Commission ,Free Report ,Gen Pharma Trading Down ,Gen Pharma ,Get Free Report ,Exchange Commission ,Global Investments Holdings ,Universal Asset Management ,Financial Markets ,Connor Clark ,Lunn Investment Management ,Gen Pharma Ltd ,Urogen Pharma Daily ,